Pre‐clinical evaluation of a themosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model

&NA; Despite clinical remission of epithelial ovarian cancer (EOC) after surgical resection and first‐line chemotherapy, about 60% of patients will re‐develop peritoneal metastasis and about 50% will relapse with chemoresistant disease. Clinical studies suggest that intra‐peritoneal (i.p.) chemotherapy effectively treats residual EOC after cyto‐reduction by gaining direct access into the peritoneal cavity, enabling elevated drug levels versus intravenous (i.v.) injection. However, chemoresistant disease is still problematic. To overcome resistance against microtubule stabilizing agents such as taxanes, epothilone B (EpoB) has merit, especially in combination with molecular targeted agents that inhibit heat shock protein 90 (Hsp90) and/or mammalian target of rapamycin (mTOR). In this paper, we report on the successful loading and solubilization of EpoB in a poly(d,l‐lactic‐co‐glycolic acid)‐block‐poly(ethylene glycol)‐block‐poly(d,l‐lactic‐co‐glycolic acid) (PLGA‐b‐PEG‐b‐PLGA) thermosensitive gel (g‐E). Further, we report on successful co‐loading of 17‐AAG (Hsp90) and rapamycin (mTOR) (g‐EAR). After i.p. injection in mice, g‐EAR showed gelation in the peritoneum and sustained, local‐regional release of EpoB, 17‐AAG, and rapamycin. In a luciferase‐expressing ES‐2 (ES‐2‐luc) ovarian cancer xenograft model, single i.p. injections of g‐E and g‐EAR delayed bioluminescence from metastasizing ES‐2‐luc cells for 2 and 3 weeks, respectively, despite fast drug release for g‐EAR in vivo versus in vitro. In summary, a PLGA‐b‐PEG‐b‐PLGA sol‐gel has loading and release capacities for EpoB and its combinations with 17‐AAG and rapamycin, enabling a platform for i.p. delivery, sustained multi‐drug exposure, and potent antitumor efficacy in an ES‐2‐luc, ovarian cancer i.p. xenograft model. Graphical abstract Anticancer effect of PLGA‐b‐PEG‐b‐PLGA thermogel containing EpoB, 17‐AAG, and rapamycin. Figure. No caption available.

[1]  D. Proia,et al.  Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib , 2014, Molecular Cancer Therapeutics.

[2]  Shen‐guo Wang,et al.  Enzymatic degradation behavior and mechanism of poly(lactide-co-glycolide) foams by trypsin. , 2003, Biomaterials.

[3]  N. Ahmed,et al.  Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research , 2013, Front. Oncol..

[4]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[5]  Suming Li,et al.  Enzymatic degradation of polylactide stereocopolymers with predominant d-lactyl contents , 2000 .

[6]  Peter Andorfer,et al.  Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer , 2016, BMC Systems Biology.

[7]  G. Kwon,et al.  Oligo(lactic acid)n-Paclitaxel Prodrugs for Poly(ethylene glycol)-block-poly(lactic acid) Micelles: Loading, Release, and Backbiting Conversion for Anticancer Activity. , 2016, Journal of the American Chemical Society.

[8]  G. Kwon,et al.  Thermosensitive poly-(d,l-lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly-(d,l-lactide-co-glycolide) hydrogels for multi-drug delivery , 2014, Journal of drug targeting.

[9]  Hirenkumar K. Makadia,et al.  Poly Lactic-co-Glycolic Acid ( PLGA ) as Biodegradable Controlled Drug Delivery Carrier , 2011 .

[10]  C. Helm,et al.  The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. , 2009, The oncologist.

[11]  F. McCormick,et al.  Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy , 2007, PloS one.

[12]  S. Tomao,et al.  Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment , 2016, Journal of Translational Medicine.

[13]  Chang-Young Jang,et al.  Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells , 2016, International journal of nanomedicine.

[14]  Micheline Piquette-Miller,et al.  Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model , 2007, Cancer Chemotherapy and Pharmacology.

[15]  E. Trimble,et al.  2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Hanqing Liu,et al.  Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer , 2013, Clinical Cancer Research.

[17]  D. Kohane,et al.  HYDROGELS IN DRUG DELIVERY: PROGRESS AND CHALLENGES , 2008 .

[18]  Y. Yeo,et al.  Drug Delivery Systems for Intraperitoneal Therapy , 2010, Pharmaceutical Research.

[19]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[20]  S. Achilefu,et al.  Proof-of-Concept of Polymeric Sol-Gels in Multi-Drug Delivery and Intraoperative Image-Guided Surgery for Peritoneal Ovarian Cancer , 2016, Pharmaceutical Research.

[21]  G. Kwon,et al.  PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Stephen Clarke,et al.  Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics , 2012, Clinical Pharmacokinetics.

[23]  F. Hartveit,et al.  Peritoneal Fluid Volume and the Oestrus Cycle in Mice , 1966, Nature.

[24]  E. Lazarides,et al.  Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. , 1995, Cancer research.

[25]  D. Alberts,et al.  Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian Cancer , 2012, Clinical Cancer Research.

[26]  U. Menon,et al.  Ovarian cancer screening—Current status, future directions☆ , 2014, Gynecologic oncology.